Employees: 379
Size Gujarat Themis Biosyn (GUJTHEM.NS) is an India Health Care company (Pharmaceuticals: Major) with a market value of $505M, the 842nd largest of 1,066 India companies the cockpit tracks. Shares closed at ₹362.80 on 18 Nov 2026.
Performance Over six months the shares gained 1.8%, against -19.6% for the median peer and +3.8% for the India market (cap-weighted) — 5th highest of 20 in its peer set.
Growth Revenue grew 17.5% over the last twelve months (peer median +9.4%); the operating margin is 38.9% (peer median 10.9%).
Valuation It trades at 27.2× enterprise value to sales against a peer median of 3.7× (2nd most expensive of 20).
Capital Return on invested capital runs 2.4 points below its cost of capital (20.0% WACC).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | ₹1.74B | ₹1.66B | ₹1.51B | ₹1.70B | ₹1.48B |
| Revenue growth | — | +10% | -11% | +14% | — |
| Gross profit | ₹822M | ₹769M | ₹737M | ₹863M | ₹797M |
| EBITDA | ₹824M | ₹772M | ₹709M | ₹788M | ₹748M |
| Net income | ₹487M | ₹467M | ₹488M | ₹592M | ₹580M |
| Free cash flow | n/a | -₹1.28B | -₹220M | -₹94.3M | ₹99.2M |
| Capital expenditure | n/a | ₹1.73B | ₹1.16B | ₹746M | ₹237M |
| Total debt | n/a | ₹1.62B | ₹305M | ₹27.7M | ₹4.19M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | GUJTHEM.NS | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +1.2% | -7.0% | 5th highest of 20 |
| 6-month return | +1.8% | -19.6% | 5th highest of 20 |
| Distance from 52-week high | -22.8% | -39.7% | 4th highest of 20 |
| Revenue growth (TTM) | +17.5% | +9.4% | 5th highest of 20 |
| Operating margin | 38.9% | 10.9% | 2nd highest of 20 |
| EV / Sales | 27.2× | 3.7× | 2nd most expensive of 20 |
| ROIC minus cost of capital | -2.4 pp | -2.2 pp | 10th highest of 19 |
| EV / EBITDA | 57.3× | 9.7× | most expensive of 5 |
| Net debt / EBITDA | 1.9× | 1.6× | 3rd most indebted of 6 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Gujarat Themis Biosyn GUJTHEM.NS | India | $505M | +2% | +18% | 39% | 27.2× | n/a | n/a |
| Indaptus Therapeutics INDP | United States | $505M | +147% | n/a | n/a | n/a | n/a | n/a |
| Shanghai Xiao Fang Pharmaceutical 603207.SS | China | $503M | -17% | +10% | 39% | 4.8× | -5.4% | +7.6% |
| Egetis Therapeutics EGTX.ST | Sweden | $509M | +76% | +27% | -645% | 71.0× | n/a | n/a |
| Gyre Therapeutics GYRE | United States | $500M | -28% | +14% | -18% | 4.0× | n/a | n/a |
| Xizang Weixinkang Pharmaceutical 603676.SS | China | $513M | -22% | -8% | 16% | 2.3× | -6.1% | +9.6% |
| Henan Taloph Pharmaceutical Stock 600222.SS | China | $497M | -21% | -5% | 7% | 2.5× | 16.7% | +4.4% |
| Alpha Teknova TKNO | United States | $496M | +113% | +15% | -32% | 11.0× | n/a | n/a |
| Jiangsu Lianhuan Pharmaceutical 600513.SS | China | $496M | -41% | +14% | 0% | 1.8× | n/a | n/a |
| Daewoong 003090.KS | South Korea | $495M | -28% | +6% | 11% | 0.9× | n/a | n/a |
| Aarti Drugs AARTIDRUGS.NS | India | $494M | +34% | +15% | 11% | 1.8× | 22.1% | +3.5% |
| Beijing Science Sun Pharmaceutical 300485.SZ | China | $517M | -29% | -11% | -8% | 5.6× | n/a | n/a |
| Shandong Wohua Pharmaceutical 002107.SZ | China | $493M | -20% | -4% | 18% | 3.7× | 5.9% | -4.1% |
| Tong Ren Tang Technologies 1666.HK | Hong Kong | $491M | -19% | -14% | 12% | 0.6× | -17.2% | +6.3% |
| Newland Pharmaceutical 301277.SZ | China | $488M | -22% | +9% | 11% | 3.5× | 8.9% | +9.1% |
| Nanjing Hicin Pharmaceutical 300584.SZ | China | $487M | -29% | +32% | 17% | 4.3× | 3.3% | -1.1% |
| Hefei Lifeon Pharmaceutical 003020.SZ | China | $486M | -21% | -1% | 10% | 2.0× | n/a | n/a |
| Evonile Pharma EVONILE.NS | India | $529M | n/a | -5% | 12% | 16.2× | 49.3% | -1.5% |
| Supriya Lifescience SUPRIYA.NS | India | $529M | -15% | +23% | 26% | 5.5× | 28.2% | +15.8% |
| Jinling Pharmaceutical 000919.SZ | China | $529M | -15% | -8% | 1% | 0.7× | 2.4% | +5.0% |
| Shanghai MicuRx Pharmaceutical 688373.SS | China | $481M | -8% | +23% | -61% | 19.0× | n/a | n/a |